These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12865895)

  • 1. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease.
    Högl B; Rothdach A; Wetter TC; Trenkwalder C
    Neuropsychopharmacology; 2003 Oct; 28(10):1866-70. PubMed ID: 12865895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease?
    Sixel-Döring F; Trautmann E; Mollenhauer B; Trenkwalder C
    Sleep Med; 2012 Oct; 13(9):1178-83. PubMed ID: 22841842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
    Romigi A; Stanzione P; Marciani MG; Izzi F; Placidi F; Cervellino A; Giacomini P; Brusa L; Grossi K; Pierantozzi M
    J Neural Transm (Vienna); 2006 Dec; 113(12):1909-13. PubMed ID: 16736238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time structure of leg movement activity during sleep in untreated Parkinson disease and effects of dopaminergic treatment.
    Puligheddu M; Figorilli M; Aricò D; Raggi A; Marrosu F; Ferri R
    Sleep Med; 2014 Jul; 15(7):816-24. PubMed ID: 24891077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial.
    Stiasny K; Röbbecke J; Schüler P; Oertel WH
    Sleep; 2000 May; 23(3):349-54. PubMed ID: 10811379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
    Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
    J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).
    Oertel WH; Benes H; Bodenschatz R; Peglau I; Warmuth R; Happe S; Geisler P; Cassel W; Leroux M; Kohnen R; Stiasny-Kolster K
    Neurology; 2006 Sep; 67(6):1040-6. PubMed ID: 16931508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study.
    Placidi F; Izzi F; Romigi A; Stanzione P; Marciani MG; Brusa L; Sperli F; Galati S; Pasqualetti P; Pierantozzi M
    J Neurol; 2008 Jul; 255(7):1032-7. PubMed ID: 18500498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease.
    Baas HK; Schueler P
    Eur Neurol; 2001; 46 Suppl 1():18-23. PubMed ID: 11741099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifecorder: a new device for the long-term monitoring of motor activities for Parkinson's disease.
    Saito N; Yamamoto T; Sugiura Y; Shimizu S; Shimizu M
    Intern Med; 2004 Aug; 43(8):685-92. PubMed ID: 15468966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
    Liguori C; Placidi F; Stefani A; Mercuri NB; Marciani MG; Stanzione P; Pierantozzi M
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1476-8. PubMed ID: 26578038
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
    Ahlskog JE; Wright KF; Muenter MD; Adler CH
    Clin Neuropharmacol; 1996 Jun; 19(3):202-12. PubMed ID: 8726539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
    Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease.
    Rabey JM; Nissipeanu P; Inzelberg R; Korczyn AD
    Clin Neuropharmacol; 1994 Jun; 17(3):286-93. PubMed ID: 9316674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
    Del Dotto P; Colzi A; Musatti E; Strolin Benedetti M; Persiani S; Fariello R; Bonuccelli U
    Clin Neuropharmacol; 1997 Oct; 20(5):455-65. PubMed ID: 9331523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.